<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166071</url>
  </required_header>
  <id_info>
    <org_study_id>SSO</org_study_id>
    <secondary_id>R21MH115287</secondary_id>
    <nct_id>NCT04166071</nct_id>
  </id_info>
  <brief_title>Opioids and Social Support Enhanced Extinction Effects</brief_title>
  <acronym>SSO</acronym>
  <official_title>Revisiting Safety Signals: Examining a Separate Safety Mechanism for Social Support Figures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      University of California, Los Angeles researchers will recruit healthy participants (age&#xD;
      18-35) to participate in a study examining whether the administration of naltrexone, an&#xD;
      opioid antagonist, eliminates the ability of social support figure reminders to enhance fear&#xD;
      extinction--a process during which a threatening cue is learned to not predict a negative or&#xD;
      threatening outcome (i.e., electric shock) by being repeatedly presented in the absence of&#xD;
      that outcome.&#xD;
&#xD;
      After undergoing an email screening, a telephone screening, an in lab screening, and a health&#xD;
      screening, 60 participants will be enrolled in the study. During the experiment, 30&#xD;
      participants will be administered naltrexone and 30 participants will be administered placebo&#xD;
      (both participants and experimenters will be blind to condition) before undergoing a fear&#xD;
      extinction procedure in which threatening cues--cues that predict electric shock--will be&#xD;
      paired with either an image of a social support figure (provided by participants) or a second&#xD;
      threatening cue. These pairings will be presented repeatedly in the absence of shock in order&#xD;
      for fear extinction to occur. Participants will return for a follow-up test to determine if&#xD;
      fear extinction was successful.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fear Response directly post-extinction</measure>
    <time_frame>Directly following a fear extinction procedure (during the experiment session).</time_frame>
    <description>presence of fear response as indicated by significantly higher galvanic skin response (GSR: an index of peripheral stress responding) to a previously learned fearful image (CS+) compared to a baseline comparator (CS-: never learned to be fearful).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fear Response 24-hours post-extinction</measure>
    <time_frame>24 hours following the completion of the fear extinction procedure (during a follow-up fear reinstatement session).</time_frame>
    <description>presence of fear response as indicated by significantly higher galvanic skin response (GSR: an index of peripheral stress responding) to a previously learned fearful image (CS+) compared to a baseline comparator (CS-: never learned to be fearful).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fear</condition>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Half of the participants will be randomly assigned to take one dose of naltrexone (50mg, capsule form) during the experimental session</description>
    <arm_group_label>Naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Half of the participants will be randomly assigned to take a placebo capsule during the experimental session</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy adults 18 and 35&#xD;
&#xD;
          -  fluent in English&#xD;
&#xD;
          -  no history of mental illness (including anxiety, depression, phobia, or any other&#xD;
             mental health related disorder diagnosed by a mental health professional)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or planning to become pregnant during the experiment period&#xD;
&#xD;
          -  presence of chronic mental illness (as determined by the report of a past diagnosis of&#xD;
             mental illness by a physician or psychologist and/or the prescription of medication&#xD;
             related to mental health disorder; including anxiety, depression, phobia, or any other&#xD;
             diagnosed psychological disorder)&#xD;
&#xD;
          -  chronic physical illness (as determined by past diagnosis and/or treatment by a&#xD;
             physician)&#xD;
&#xD;
          -  history of liver disease or abnormal liver function&#xD;
&#xD;
          -  current and regular use of prescription medications related to mental health disorders&#xD;
             or liver function&#xD;
&#xD;
          -  previous history of fainting during blood draws&#xD;
&#xD;
          -  difficulty or discomfort swallowing pills&#xD;
&#xD;
          -  history of substance abuse or addiction (especially alcohol or opiate abuse)&#xD;
&#xD;
        Other exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Eisenberger, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erica Hornstein, Ph.D.</last_name>
    <phone>9175664470</phone>
    <email>ericahornstein@ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Department of Psychology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Naomi Eisenberger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>social support</keyword>
  <keyword>fear extinction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

